Depressive Disorder, MajorPhase 3NCT02709655
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)
A Phase 3 study testing Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20mg/day in people with Depressive Disorder, Major, run by H. Lundbeck A/S at 98 sites in 19 countries.
Trial summary
Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years). Read more about this study
- Who is it for?
- Ages 7 to 11 years
- Conditions the study is for
- Depressive Disorder, Major
- What is being tested?
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20mg/day
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 683 participants
- Where
- 98 sitesin 19 countries
- Study dates
- 18 May 2016to 21 Jan 2022
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 11 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- The participant has MDD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5™).
- The participant has a CDRS-R total score ≥45 at the Screening Visit and the Baseline.
- The participant has a CGI-S score ≥4 at the Screening Visit and the Baseline.
- The participant is a boy or girl, aged ≥7 and <12 years at Screening Visit
- The participant has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form.
Who cannot join
- The participant has participated in a clinical study <30 days prior to the Screening Visit.
- The participant has previously participated in a study with vortioxetine.
- Other protocol defined inclusion and exclusion criteria may apply
Trial locations and contacts
98 sites in 19 countries.
98 sites in 19 countries
United States34 sites
Atlanta Center for Medical Research
Atlanta, Georgia, 30331
BioBehavioral Research of Austin
Austin, Texas, 78759
Kennedy Krieger Institute
Baltimore, Maryland, 21205
American Medical Research, Inc.
Chicago, Illinois, 60612
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219
University Hospital Cleveland Medical Center Division of Child and Adolescent Psychiatry
Cleveland, Ohio, 44012
Westside Medical
Clinton, Utah, 84015
Sarkis Clinical Trials
Gainesville, Florida, 32607
Sun Valley Research Center
Imperial, California, 92251
Lake Charles Clinical Trials
Lake Charles, Louisiana, 70629
Synergy Clinical Research Center
Lemon Grove, California, 91945
Woodland International Research Group
Little Rock, Arkansas, 72211
Alliance for Wellness dba Alliance for Research
Long Beach, California, 90807
Northwest Behavioral Research Center
Marietta, Georgia, 30060
Research Strategies Of Memphis, Llc
Memphis, Tennessee, 38119
North Star Medical Research, LLC
Middleburg Heights, Ohio, 44130
AMR- Baber Research, Inc.
Naperville, Illinois, 60563
Manhattan Behavioral Medicine
New York, New York, 10036
IPS Research Company
Oklahoma City, Oklahoma, 73106
Paradigm Research Professionals, LLC
Oklahoma City, Oklahoma, 73118
NRC Research Institute
Orange, California, 92868
Medical Research Group of Central Florida
Orange City, Florida, 32763
Aspen Clinical Research, LLC
Orem, Utah, 84058
Asclepes Research Center
Panorama City, California, 91402
AIM Trials, LLC
Plano, Texas, 75093
Research Across America
Plano, Texas, 75093
Princeton Medical Institute
Princeton, New Jersey, 08540
Finger Lakes Clinical Research
Rochester, New York, 14618
St. Charles Psychiatric Associates - Midwest Research Group
Saint Charles, Missouri, 63304
Clinical Trials of Texas, Inc.
San Antonio, Texas, 78229
Millennium Psychiatric Associates, LLC
St Louis, Missouri, 63132
AMR Conventions Research
Warrenville, Illinois, 60555
Children's National Medical Center Merge
Washington D.C., District of Columbia, 20010
Kansas University School of Medicine-Wichita
Wichita, Kansas, 67214
Russia13 sites
Arkhangelsk Regional Clinical Mental Hospital
Arkhangelsk, 163530
GUZ Engels Psychiatric Hospital
Engel's, 413124
State Budgetary Healthcare Institution (SBHI) Specialized Clinical Psychiatric Hospital 1 of the ...
Krasnodar, 350007
LLC City Neurological Center Sibneuromed
Novosibirsk, 630091
Medicorehabilitation Research Center Phoenix
Rostov-on-Don, Rostov State, 344010
Rostov State Medical University of the Minzdravsotsrazvitiya of Russia
Rostov-on-Don, 344022
City Psychiatric Hospital No.3 named after I.I. Skvortsov-Stepanov
Saint Petersburg, 197341
Saratov State Medical University
Saratov, 410028
Guz Saratov Regional Psychiatric Hospital St. Sofii
Saratov, 410060
Stavropol Region Psychiatric Hospital No.2
Stavropol, Stavropol Kray, 357034
Nebbiolo LLC
Tomsk, 634009
Yaroslavl Regional Clinical Psychiatry Hospital
Yaroslavl, 150003
State Budgetary Healthcare Institution of Sverdlovsk Region ¿Sverdlovsk Regional Clinical Psychi...
Yekaterinburg, 620030
Mexico9 sites
ICARO Investigaciones en Medicina S.A. de C.V.
Chihuahua City, 31000
Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C
Culiacan de Rosales, Sinaloa, 80230
Centro Investigacion Medico Biologica Y Terapia Avanzada
Guadalajara, Jalisco, 44130
Clinica Cemelli
Guadalajara, Jalisco, 44200
Roberto Zepeda Sanchez
Guadalajara, Jalisco, 44690
B & B Investigaciones Medicas, SC
Mazatlán, Sinaloa, 82140
Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics)
Mexico City, Mexico City, 04530
CRI Centro Regiomontano de Investigacion SC
Monterrey, Nuevo León, 64060
BIND Investigaciones S.C
San Luis Potosí City, 78213
Poland6 sites
Prywatne Gabinety Lekarskie Promedicus
Bialystok, Podlaskie Voivodeship, 15879
Centrum Badan Klinicznych PI-House Sp. z o.o.
Gdansk, 80-546
Przychodnia Syntonia Poradnia Zdrowia Psychicznego
Kielce, 25-103
Spectrum Centrum Psychiatrii Specjalistyczny Gabinet Psychiatryczny
Lublin, 20-884
Filip Rybakowski Specjalistyczna Praktyka Lekarska
Poznan, 60-744
Specjalistyczny Szpital im. dra A. Sokolowskiego w Walbrzychu
Wałbrzych, 58300
Serbia5 sites
Child and Adolescent Neurology and Psychiatry Clinic
Belgrade, 11000
Institute of Mental Health
Belgrade, 11000
University Clinical Center Kragujevac
Kragujevac, 34000
Clinical Center of Vojvodina - Clinic of Psychiatry
Novi Sad, 21000
Daily Hospital for Children and Adolescents
Pantelej-Nis, 18000
Colombia4 sites
Centro de Investigaciones y Proyectos en Neurociencias CIPNA LTDA IPS.
Barranquilla, Atlántico, 80020
E.S.E. Hospital Mental de Antioquia HOMO
Bello, Antioquia, 51050
Centro de investigaciones del Sistema Nervioso SAS Grupo CISNE SAS
Bogotá, DC, 111166
Psynapsis Salud Mental S.A.
Pereira, Risaralda Department
Ukraine4 sites
Ukrainian Research Institute Of Social, Forensic Psychiatry And Drug Abuse, Kiev City Psychoneuro...
Kyiv, 04080
Odessa Regional Medical Centre of Mental Health
Odesa, 65006
Maltsev Poltava Regional Clinical Psychiatric Hospital, Higher State Educational Institution Of U...
Poltava, 36013
Ternopil Regional Clinical Municipal Psycho-Neurological Hospital, Ternopil State Medical Univers...
Ternopil, 46000
France3 sites
Cabinet Psyche
Douai, Nord, 59500
Centre Medical Ambroise Pare
Élancourt, 78990
CHU de Nantes - Hopital Hotel Dieu
Nantes, 44093
Israel3 sites
Shalvata Mental Health Center
Hod HaSharon, 4534708
Ramat Chen - Mental Health Clinic
Tel Aviv, 6435807
The Chaim Sheba Medical Center - The Edmond and Lily Safra Children's Hospital
Tel HaShomer, 5262000
Italy3 sites
Scientific Institute Fondazione Stella Maris
Calambrone Pisa, Pisa, 56026
University Federico II Of Naples
Naples, 80131
Sciaf Ulss 16 Padova
Padova, Regione Veneto, 35143
Bulgaria2 sites
MHAT Targovishte AD
Targovisthe, 7700
Diagnostic Consultative Center Mladost-M Varna OOD
Varna, 9020
Hungary2 sites
Vadaskert Alapitvany
Budapest, 1021
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
Gyula, 5700
Latvia2 sites
Linda Keruze's Psychiatric Center, LLC
Liepāja, LV-3401
Children Hospilal -Gailezers
Riga, 1079
South Africa2 sites
Cape Trial Centre
Bellville, Cape Town, 7530
Tara Hospital
Sandhurst, Gauteng, 2196
Spain2 sites
Hospital Universitario Fundacion Alcorcon
Alcorcón, Madrid, 28922
Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo
Torremolinos, Malaga, 29620
Germany1 site
Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri
Mainz, 55122
About this study
Official title: Interventional, Randomized, Double-blind, Placebo-controlled, Active-reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years, With Major Depressive Disorder (MDD)
Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).
- Conditions
- Depressive Disorder, Major
- Being tested
- Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo
- Keywords
- paediatric
- Medical subject headings
- Depressive Disorder, Major
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vortioxetine 10 mg/dayDrug
Also called Brintellix ®, Lu AA21004
10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).
Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Vortioxetine 20 mg/dayDrug
Also called Brintellix ®, Lu AA21004
20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).
Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Fluoxetine 20mg/dayDrug
20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).
Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
PlaceboOther
Encapsulated tablet, orally
| Study group | Role | What they receive |
|---|---|---|
| Vortioxetine 10 mg/day | Experimental | Not described Receives: Drug: Vortioxetine 10 mg/day |
| Vortioxetine 20 mg/day | Experimental | Not described Receives: Drug: Vortioxetine 20 mg/day |
| Fluoxetine 20 mg/day, | Active comparator | A decision has been taken to stop recruitment into this treatment arm. Receives: Drug: Fluoxetine 20mg/day |
| Placebo | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B
The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was estimated using a restricted maximum likelihood (REML)-based Mixed Model Repeated Measurements (MMRM) approach.
Measured: Baseline (Week 4 of Phase A), Week 8 of Phase B
Secondary outcomes (20)
Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B
The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).
Measured: Baseline (Week 4 of Phase A), Weeks 2, 4, and 6 of Phase B
Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B
The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Four subscores were defined based on the CDRS-R: Mood: sum of items 8, 11, 14, 15; score range 4 to 28, Somatic: sum of items 4, 5, 6, 7, 16, 17; score range 6 to 36, Subjective: sum of items 9, 10, 12, 13; score range 4 to 28, and Behaviour: sum of items 1, 2, 3; score range 3 to 21. Higher scores indicated the most severe measure of depression.
Measured: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Percentage of Participants With CDRS-R Response
CDRS-R response was defined as a ≥50% decrease in CDRS-R total score, calculated as: (change from baseline [Randomization])/(baseline value - 17). The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).
Measured: Weeks 2, 4, 6, and 8 of Phase B
Percentage of Participants With CDRS-R Remission
CDRS-R remission was defined as a CDRS-R total score ≤28. The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).
Measured: Weeks 2, 4, 6, and 8 of Phase B
Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B
The GBI 10-item depression scale was developed to screen for depressive symptoms in children and adolescents. Two versions of the GBI 10-item depression scale were used, the child rated version (CGBI) and the parent rated version (PGBI). The 10 depression items were rated on a 4-point scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranged from 0 to 30, with higher scores indicating greater pathology.
Measured: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Parent Global Assessment (PGA) Score
The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of symptoms using a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Measured: Weeks 2, 4, 6, and 8 of Phase B
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B
The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).
Measured: Baseline (Week 4 of Phase A), Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Clinical Global Impression - Global Improvement (CGI-I) Score
The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Measured: Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Percentage of Participants With CGI-S Remission
CGI-S remission was defined as a CGI-S score of 1 or 2. The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).
Measured: Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B
The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B
The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B
The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarise their experience in a global rating. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1 to 14 is 14 to 70, with higher scores indicating greater satisfaction.
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B
The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarize their experience in a global rating. Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).
Measured: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2016 (estimated)
- Study start18 May 2016
- Primary completion21 Jan 2022
- Study completion21 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Depressive Disorder, MajorStudies of the same condition, open and under way.
- More trials run by H. Lundbeck A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 683 participants (actual)
Sponsor and investigators
- Lead sponsor
- H. Lundbeck A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Takeda
- Responsible party
- Sponsor
- Investigators
- Email contact via Lundbeck A/S, Study director, LundbeckClinicalTrials@Lundbeck.com
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02709655
- Sponsor's protocol ID
- 12709A
- Other IDs
- 2008-005353-38, 2008
- Status last verified
- Aug 2022
- First submitted
- 11 Mar 2016
- Last updated
- 22 Sep 2022
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Huss M, Findling RL, DelBello MP, Necking O, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study. JAACAP Open. 2024 Nov 22;3(3):736-748. doi: 10.1016/j.jaacop.2024.11.002. eCollection 2025 Sep.
PubMed 40922774
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Interventional, Randomized, Double-blind, Placebo-controlled, Active-reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years, With Major Depressive Disorder (MDD)
- ClinicalTrials.gov ID
- NCT02709655
- Acronym / sponsor ID
- 12709A
- Conditions
- Depressive Disorder, Major
- Keywords
- paediatric
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 683 participants (actual)
- Lead sponsor
- H. Lundbeck A/SIndustry (pharma, biotech, devices)
- Collaborators
- Takeda
- Study start
- 18 May 2016 (actual)
- Primary completion
- 21 Jan 2022 (actual)
- Study completion
- 21 Jan 2022 (actual)
- First posted
- 16 Mar 2016 (estimated)
- Results
- Posted 22 Sep 2022
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Vortioxetine 10 mg/day | Experimental | Drug: Vortioxetine 10 mg/day |
| Vortioxetine 20 mg/day | Experimental | Drug: Vortioxetine 20 mg/day |
| Fluoxetine 20 mg/day, | Active comparator | Drug: Fluoxetine 20mg/dayA decision has been taken to stop recruitment into this treatment arm. |
| Placebo | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 7 to 11 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- The participant has MDD, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5™).
- The participant has a CDRS-R total score ≥45 at the Screening Visit and the Baseline.
- The participant has a CGI-S score ≥4 at the Screening Visit and the Baseline.
- The participant is a boy or girl, aged ≥7 and <12 years at Screening Visit
- The participant has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form.
Key exclusion criteria (3 listed)
- The participant has participated in a clinical study <30 days prior to the Screening Visit.
- The participant has previously participated in a study with vortioxetine.
- Other protocol defined inclusion and exclusion criteria may apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vortioxetine 10 mg/dayAlso: Brintellix ®, Lu AA2100410 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed | Drug | Vortioxetine 10 mg/day |
| Vortioxetine 20 mg/dayAlso: Brintellix ®, Lu AA2100420 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed | Drug | Vortioxetine 20 mg/day |
| Fluoxetine 20mg/day20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed | Drug | Fluoxetine 20 mg/day, |
| PlaceboEncapsulated tablet, orally | Other | Placebo |
Primary outcome
Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Week 8 of Phase B
The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was estimated using a restricted maximum likelihood (REML)-based Mixed Model Repeated Measurements (MMRM) approach.
20 secondary outcomes
Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 2, 4, and 6 of Phase B
Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Percentage of Participants With CDRS-R Response
Time frame: Weeks 2, 4, 6, and 8 of Phase B
Percentage of Participants With CDRS-R Remission
Time frame: Weeks 2, 4, 6, and 8 of Phase B
Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Parent Global Assessment (PGA) Score
Time frame: Weeks 2, 4, 6, and 8 of Phase B
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Clinical Global Impression - Global Improvement (CGI-I) Score
Time frame: Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Percentage of Participants With CGI-S Remission
Time frame: Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B
Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 40922774Huss M, Findling RL, DelBello MP, Necking O, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study. JAACAP Open. 2024 Nov 22;3(3):736-748. doi: 10.1016/j.jaacop.2024.11.002. eCollection 2025 Sep.
Related trials for Depressive Disorder, Major
RecruitingPhase 1
Open-Label Psilocybin Study in Transdiagnostic Population
Transdiagnostic, Depression - Major Depressive Disorder
Not yet recruitingPhase 2
Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies
PTSD, PTSD - Post Traumatic Stress Disorder
RecruitingPhase 2
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Major Depressive Episode (MDE), Major Depressive Disorder (MDD)
RecruitingPhase 1
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Depression, Major Depressive Disorder
Not yet recruiting
Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression.
Major Depressive Disorder (MDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Email contact via Lundbeck A/S study director
LundbeckClinicalTrials@Lundbeck.com
98 sites in 19 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Vortioxetine 10 mg/day, Vortioxetine 20 mg/day and Fluoxetine 20mg/day in people with Depressive Disorder, Major, run by H. Lundbeck A/S at 98 sites in 19 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 98 sites in United States, Russia, Mexico, Poland, Serbia and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Sep 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B (time frame: Baseline (Week 4 of Phase A), Week 8 of Phase B). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02709655, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2022.